Startseite Kongressberichte & Archiv 23rd Congress of EHA Important Multiple Myeloma Presentations New therapeutic strategies to improve the outcome of relapsed/refractory plasma cell disorders

New therapeutic strategies to improve the outcome of relapsed/refractory plasma cell disorders

OPTIMISMM: PHASE 3 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW‐DOSE DEXAMETHASONE VS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN LENALIDOMIDE-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author(s): Paul Richardson, et al. ABSTRACT

Conclusion
The OPTIMISMM phase 3 study in early RRMM reported a significant and clinically meaningful PFS improvement in patients who were entirely LEN exposed, including 70% of patients who were refractory to LEN. Of note, the PFS and overall response rate results showed improved benefit with PVd over Vd in patients who had only 1 prior line of treatment. Follow-up for long-term survival is ongoing. The safety of POM-based treatment was manageable and consistent with its well-established profile.

 
2-hour infusions of MOR202 administered at up to 16 mg/kg with Dex or in combination with an IMiD/Dex in heavily pretreated pts with RRMM showed a favorable safety profile, including excellent infusion tolerability. Promising preliminary efficacy and long-lasting tumor control were observed.
 
Author(s): Maria-Victoria Mateos, et al.  ABSTRACT
 
Conclusion
Once-weekly Kd at 20/70 mg/m2 significantly improved PFS and ORR vs twice-weekly Kd at 20/27 mg/m2. The incidence of AEs was comparable between groups. No new safety risks were found in the once-weekly group. Overall, once-weekly Kd showed favorable benefit-risk profile with a convenient dosing regimen vs twice-weekly Kd.
 
Author(s): Joseph Mikhael, et al. ABSTRACT
 
Conclusion
These final results confirm the promising clinical activity and manageable safety profile of ISA in combination with Pom/dex in heavily pretreated RRMM. A Phase III confirmatory trial is ongoing with results expected later in 2018.
 
Author(s): Arnaud Jaccard, et al. ABSTRACT
 
Conclusion
Monotherapy with DARA demonstrates encouraging efficacy in previously-treated patients with AL amyloidosis with deep and rapid hematological responses. The administration of DARA in these patients is associated with a good safety profile and non-severe adverse events occurring mostly after the first infusion. The data, in particular hematological and organ responses, will be updated at the meeting. A prospective randomized international phase III study (AMY3001) in naive patients with DARA in combination with bortezomib, cyclophosphamide and dexamethasone is ongoing.